Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre
Monica Muntean, Violeta Briciu, Mihaela Lupse, Doina Colcear, Raul Vlad Macicasan, Agnes Csiszer, Alexandra Manole, Amanda Radulescu
Pharmaceuticals, doi:10.3390/ph17010003
The aim of this study was to ascertain patient characteristics, outcomes, and liver injuries in patients infected with different SARS-CoV-2 variants. Data from consecutive adult patients with severe/critical COVID-19 admitted to our hospital during the peak month of the Delta wave were compared to the ancestral, Alpha, and Omicron waves. The dataset of 551 hospitalized patients was similar in the Delta/non-Delta waves. At admission and discharge, the median aminotransferase levels were normal or slightly increased. During the Delta wave (172 vs. 379 non-Delta patients), more patients died (OR 1.69, 95%CI 1.09-2.56) or had liver injury at discharge (alanine aminotransferase, ALT ≥ 2 ULN) (OR 1.97, 95%CI 1.08-3.54). In-hospital mortality was associated with age, lung injury, intensive care unit admission, number of and cardiovascular comorbidities, diabetes, chronic kidney disease, and all inflammatory biomarkers. Serious liver injury at admission (ALT ≥ 5 × ULN) was significantly associated with in-hospital mortality (OR = 7.9, 95%CI 2-28.9). At discharge, drug-induced liver injury (DILI) was found in patients treated with remdesivir, ALT ≥ 2 ULN (OR = 2.62, 95%CI 1.22-5.75). Treatment with dexamethasone, remdesivir, and immunomodulators showed improved survival, OR = 0.50 (95%CI 0.33-0.77). Regardless of the variant and treatment options, less than 2% of patients displayed serious liver injury, which was not found to be a death predictor in multivariable analysis.
Conflicts of Interest: The authors declare no conflict of interest.
References
Ahlstrand, Cajander, Cajander, Ingberg, Löf et al., Visual scoring of chest CT at hospital admission predicts hospitalization time and intensive care admission in COVID-19, Infect. Dis,
doi:10.1080/23744235.2021.1910727Amri, Bégin, Tessier, Vachon, Villeneuve et al., Use of Early Donated COVID-19 Convalescent Plasma Is Optimal to Preserve the Integrity of Lymphatic Endothelial Cells, Pharmaceuticals,
doi:10.3390/ph15030365Baldelli, Marjot, Barnes, Barritt, Webb et al., SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes, Gut Liver,
doi:10.5009/gnl220327Batool, Vuthaluru, Hassan, Bseiso, Tehseen et al., Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials, Cureus,
doi:10.7759/cureus.33676Bennett, Moffitt, Hajagos, Amor, Anand et al., (N3C) Consortium. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection among US Adults Using Data From the US National COVID Cohort Collaborative, JAMA Netw. Open,
doi:10.1001/jamanetworkopen.2021.16901Bergamaschi, Mescia, Turner, Hanson, Kotagiri et al., Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease, Immunity,
doi:10.1016/j.immuni.2021.05.010Bhaskaran, Bacon, Evans, Bates, Rentsch et al., Factors associated with deaths due to COVID-19 versus other causes: Population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform, Lancet Reg. Health Eur,
doi:10.1016/j.lanepe.2021.100109Bhimraj, Morgan, Shumaker, Baden, Cheng et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Briciu, Leucuta, Muntean, Radulescu, Cismaru et al., Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting, Pathogens,
doi:10.3390/pathogens12121453Briciu, Topan, Calin, Dobrota, Leucuta et al., Comparison of COVID-19 Severity in Vaccinated and Unvaccinated Patients during the Delta and Omicron Wave of the Pandemic in a Romanian Tertiary Infectious Diseases Hospital, Healthcare,
doi:10.3390/healthcare11030373Chaibi, Boussier, Hajj, Abitbol, Taieb et al., Liver function test abnormalities are associated with a poorer prognosis in COVID-19 patients: Results of a French cohort, Clin. Res. Hepatol. Gastroenterol,
doi:10.1016/j.clinre.2020.10.002Chew, Tang, Radcliffe, Caruana, Doilicho et al., Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated with Liver Insufficiency or Death, Clin. Gastroenterol. Hepatol,
doi:10.1016/j.cgh.2021.05.022Conrozier, Lohse, Balblanc, Dussert, Royer et al., Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): Results of a multidisciplinary collaboration, Clin. Exp. Rheumatol
Core, A Language and Environment for Statistical Computing
Crisan, Avram, Grapa, Dragan, Radulescu et al., Liver Injury and Elevated FIB-4 Define a High-Risk Group in Patients with COVID-19, J. Clin. Med,
doi:10.3390/jcm11010153Deng, Lin, Mai, Liu, Chen, Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients, Eur. J. Gastroenterol. Hepatol,
doi:10.1097/MEG.0000000000002381Ebrahimi, Simon, Hagström, Söderling, Wester et al., Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Population-based Cohort Study, Clin. Gastroenterol. Hepatol,
doi:10.1016/j.cgh.2023.05.013Ekpanyapong, Bunchorntavakul, Reddy, COVID-19 and the liver: Lessons learnt from the EAST and the WEST, a year later, J. Viral Hepat,
doi:10.1111/jvh.13590Fu, Zhu, Bai, Han, He et al., Clinical features of patients infected with coronavirus disease 2019 with elevated liver biochemistries: A multicenter, retrospective study, Hepatology,
doi:10.1002/hep.31446Gabrielli, Franza, Esperide, Gasparrini, Gasbarrini et al., Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy, Vaccines,
doi:10.3390/vaccines10020192Gottlieb, Vaca, Paredes, Mera, Webb et al., GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N. Engl. J. Med,
doi:10.1056/NEJMoa2116846Hamming, Timens, Bulthuis, Lely, Navis et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. Pathol,
doi:10.1002/path.1570Hermine, Mariette, Tharaux, Resche-Rigon, Porcher et al., Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial, JAMA Intern. Med,
doi:10.1001/jamainternmed.2020.6820Idalsoaga, Ayares, Arab, Díaz, COVID-19 and indirect liver injury: A narrative synthesis of the evidence, J. Clin. Transl. Hepatol,
doi:10.14218/JCTH.2020.00140Imam, Almalki, Alzahrani, Al-Ghamdi, Falemban et al., COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications, Int. Immunopharmacol,
doi:10.1016/j.intimp.2023.110439Karlafti, Paramythiotis, Pantazi, Georgakopoulou, Kaiafa et al., Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection, Medicina,
doi:10.3390/medicina58121848Kotfis, Karolak, Lechowicz, Zegan-Bara Ńska, Pikulska et al., Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial, Pharmaceuticals,
doi:10.3390/ph15020200Kulkarni, Kumar, Tevethia, Premkumar, Arab et al., Systematic review with meta-analysis: Liver manifestations and outcomes in COVID-19, Aliment. Pharmacol. Ther,
doi:10.1111/apt.15916Laffont-Lozes, Laureillard, Loubet, Stephan, Chiaruzzi et al., Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France, Antibiotics,
doi:10.3390/antibiotics12010088Legislativ, Protocol of Treatment of SARS-CoV-2 Infection
Lei, Liu, Zhou, Qin, Zhang et al., Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China, Hepatology,
doi:10.1002/hep.31301Liakina, Stundiene, Milaknyte, Bytautiene, Reivytyte et al., Effects of COVID-19 on the liver: The experience of a single center, World J. Gastroenterol,
doi:10.3748/wjg.v28.i39.5735Liatsos, SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups, World J. Gastroenterol,
doi:10.3748/wjg.v29.i16.2397Loomba, Villarreal, Farias, Aggarwal, Aggarwal et al., Serum biomarkers for prediction of mortality in patients with COVID-19, Ann. Clin. Biochem,
doi:10.1177/00045632211014244Malik, Patel, Mehta, Patel, Kelkar et al., Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis, BMJ Evid.-Based Med,
doi:10.1136/bmjebm-2020-111536Marjot, Webb, Barritt, Moon, Stamataki et al., COVID-19 and liver disease: Mechanistic and clinical perspectives, Nat. Rev. Gastroenterol. Hepatol,
doi:10.1038/s41575-021-00426-4Martínez-Sanz, Muriel, Ron, Herrera, Perez-Molina et al., Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A multicentre cohort study, Clin. Microbiol. Infect,
doi:10.1016/j.cmi.2020.09.021Mihai, Tiliscan, Visan, Stratan, Ganea et al., Evaluation of Drug-Induced Liver Injury in Hospitalized Patients with SARS-CoV-2 Infection, Microorganisms,
doi:10.3390/microorganisms10102045Moga, Foncea, Bende, Popescu, Burdan et al., Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis, Diagnostics,
doi:10.3390/diagnostics13040600Moreno Diaz, Amor García, Teigell Muñoz, Saldana Perez, Gonzalez et al., Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19, Eur. J. Hosp. Pharm,
doi:10.1136/ejhpharm-2020-002669Nab, Parker, Andrews, Hulme, Fisher et al., Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: A retrospective cohort study using the OpenSAFELY platform, Lancet Public Health,
doi:10.1016/S2468-2667(23)00079-8Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed antiviral drugs for COVID-19-Interim WHO Solidarity Trial Results, N. Engl. J. Med,
doi:10.1056/NEJMoa2023184Papagiouvanni, Kotoulas, Pataka, Spyratos, Porpodis et al., COVID-19 and liver injury: An ongoing challenge, World J. Gastroenterol,
doi:10.3748/wjg.v29.i2.257Paranga, Pavel-Tanasa, Constantinescu, Plesca, Petrovici et al., Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants, Front. Immunol,
doi:10.3389/fimmu.2023.1213246Phipps, Barraza, Lasota, Sobieszczyk, Pereira et al., Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort, Hepatology,
doi:10.1002/hep.31404Ponziani, Del Zompo, Nesci, Santopaolo, Ianiro et al., Gemelli against COVID-19" group. Liver involvement is not associated with mortality: Results from a large cohort of SARS-CoV-2-positive patients, Aliment. Pharmacol. Ther,
doi:10.1111/apt.15996Radulescu, Istrate, Muntean, Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2022.01.048Radulescu, Lupse, Istrate, Calin, Topan et al., Validation of Mortality Scores among High-Risk COVID-19 Patients: A Romanian Retrospective Study in the First Pandemic Year, J. Clin. Med,
doi:10.3390/jcm11195630Roca-Fernández, Dennis, Nicholls, Mcgonigle, Kelly et al., Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19, Front. Med,
doi:10.3389/fmed.2021.636637Salton, Confalonieri, Campisciano, Cifaldi, Rizzardi et al., Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS, J. Clin. Med,
doi:10.3390/jcm11112951Shah, Orton, Grinsztejn, Donaldson, Ramírez et al., Favipiravir in patients hospitalised with COVID-19 (PIONEERtrial): A multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care, Lancet Respir. Med,
doi:10.1016/S2213-2600(22)00412-XShehab, Alrashed, Shuaibi, Alajmi, Barkun, Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: Systematic review and meta-analysis, BMJ Open Gastroenterol,
doi:10.1136/bmjgast-2020-000571Tleyjeh, Kashour, Damlaj, Riaz, Tlayjeh et al., Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis, Clin. Microbiol. Infect,
doi:10.1016/j.cmi.2020.10.036Turtle, Thorpe, Drake, Swets, Palmieri et al., Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study, PLoS Med,
doi:10.1371/journal.pmed.1004086Tuteja, Yu, Wilson, Chen, Wendt et al., Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19, Clin. Transl. Sci,
doi:10.1111/cts.13313Vadiraj, Thareja, Raman, Karantha, Jayaraman et al., Does Raised Transaminases Predict Severity and Mortality in Patients with COVID-19?, J. Clin. Exp. Hepatol,
doi:10.1016/j.jceh.2022.01.004Veklury, Package Insert
Vijayaraghavan, Bishnu, Baruch, Citarella, Kartsonaki et al., Liver injury in hospitalized patients with COVID-19: An International observational cohort study, PLoS ONE
Vitiello, La Porta, D'aiuto, Ferrara, The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt, Liver J,
doi:10.1186/s43066-021-00082-yWanner, Andrieux, Badia-I-Mompel, Edler, Pfefferle et al., Molecular consequences of SARS-CoV-2 liver tropism, Nat. Metab,
doi:10.1038/s42255-022-00552-6Weber, Hellmuth, Scherer, Muenchhoff, Mayerle et al., Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: A prospective cohort study, Gut,
doi:10.1136/gutjnl-2020-323800Who, Clinical Management of COVID-19, Living Guideline
Who, Working Group on the Clinical Characterisation and Management of COVID-19 infection, a minimal common outcome measure set for COVID-19 clinical research, Lancet Infect. Dis,
doi:10.1016/S1473-3099(20)30483-7Wijarnpreecha, Ungprasert, Panjawatanan, Harnois, Zaver et al., COVID-19 and liver injury: A meta-analysis, Eur. J. Gastroenterol. Hepatol,
doi:10.1097/MEG.0000000000001817Xu, Huang, Fei, Li, Chen, Dynamic Changes in Liver Function Tests and Their Correlation with Illness Severity and Mortality in Patients with COVID-19: A Retrospective Cohort Study, Clin. Interv. Aging,
doi:10.2147/CIA.S303629Zhao, Li, Li, Su, Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments, World J. Gastroenterol,
doi:10.3748/wjg.v29.i2.241
